Inflammation plays a key role in the development and progression of diabetic cardiomyopathy, presenting a potential target for therapeutic intervention.
Supports anti-inflammatory therapy exploration in diabetic cardiomyopathy; leaves open confirmation of clinical benefit in prospective trials.
Type 2 diabetes mellitus (T2DM) is a major risk factor for developing cardiovascular disease and represents a serious public health problem, with high rates of mortality and morbidity worldwide. T2DM etiology is complex and multifactorial and is associated with several complications, including those at myocardium level. Diabetic cardiomyopathy (DCM) is viewed as a specific cardiomyopathy and defined as structural and functional changes in the myocardium due to metabolic and cellular abnormalities induced by diabetes. T2DM has long been classified as an inflammatory disease and recent studies have identified the importance of the inflammatory process in the development and progression of heart failure. In this review, the authors outline the main mechanisms underlying the potential contribution of the inflammatory process in the development and evolution of DCM. In addition, potential therapeutic strategies against inflammation of DCM are discussed.
No takes yet. Share an insight, caveat, or question.
Flávio Reis (2012) studied this question.
Synapse has enriched 4 closely related papers on similar clinical questions. Consider them for comparative context: